ES2526566T3 - Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90 - Google Patents

Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90 Download PDF

Info

Publication number
ES2526566T3
ES2526566T3 ES10768357.5T ES10768357T ES2526566T3 ES 2526566 T3 ES2526566 T3 ES 2526566T3 ES 10768357 T ES10768357 T ES 10768357T ES 2526566 T3 ES2526566 T3 ES 2526566T3
Authority
ES
Spain
Prior art keywords
compound
paclitaxel
triazole
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10768357.5T
Other languages
English (en)
Spanish (es)
Inventor
Ronald K. Blackman
Kevin Paul Foley
David Proia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Application granted granted Critical
Publication of ES2526566T3 publication Critical patent/ES2526566T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES10768357.5T 2009-10-19 2010-10-19 Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90 Active ES2526566T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27933009P 2009-10-19 2009-10-19
US279330P 2009-10-19
US33577810P 2010-01-11 2010-01-11
US335778P 2010-01-11
PCT/US2010/053199 WO2011049946A1 (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds

Publications (1)

Publication Number Publication Date
ES2526566T3 true ES2526566T3 (es) 2015-01-13

Family

ID=43218142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10768357.5T Active ES2526566T3 (es) 2009-10-19 2010-10-19 Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90

Country Status (21)

Country Link
US (1) US20120245186A1 (https=)
EP (1) EP2490688B1 (https=)
JP (2) JP2013508378A (https=)
KR (1) KR20120093970A (https=)
CN (1) CN102695504A (https=)
AU (1) AU2010308306A1 (https=)
BR (1) BR112012009215A2 (https=)
CA (1) CA2779233A1 (https=)
CY (1) CY1115902T1 (https=)
DK (1) DK2490688T3 (https=)
EA (1) EA022119B1 (https=)
ES (1) ES2526566T3 (https=)
HR (1) HRP20141150T1 (https=)
MX (1) MX2012004577A (https=)
NZ (2) NZ622713A (https=)
PH (1) PH12012500748A1 (https=)
PL (1) PL2490688T3 (https=)
PT (1) PT2490688E (https=)
RS (1) RS53716B1 (https=)
SI (1) SI2490688T1 (https=)
WO (1) WO2011049946A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するピラゾール化合物
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
EP2035396B1 (en) 2006-05-25 2014-05-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2026797A2 (en) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
ES2415234T3 (es) * 2008-08-08 2013-07-24 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad Hsp90
US8106083B2 (en) 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2011146803A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
WO2011146801A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
US20120064175A1 (en) * 2010-05-20 2012-03-15 Synta Pharmaceuticals Corp. HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
WO2011149824A1 (en) * 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2714033A1 (en) * 2011-05-26 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2014520808A (ja) * 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Hsp90阻害化合物を用いた癌の治療
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
EA201890454A1 (ru) 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
CN105237533B (zh) * 2015-10-26 2017-03-22 中国药科大学 四氢吡啶并[4,3‑d]嘧啶类Hsp90抑制剂及其医药用途
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007267843B2 (en) * 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
TW200901960A (en) * 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2009002321A1 (en) 2007-06-27 2008-12-31 Thomson Licensing Enhancing image quality
CN101801983B (zh) * 2007-08-13 2014-01-29 辛塔制药公司 调控hsp90活性的三唑化合物
JP2014520808A (ja) * 2011-07-07 2014-08-25 シンタ ファーマシューティカルズ コーポレーション Hsp90阻害化合物を用いた癌の治療

Also Published As

Publication number Publication date
CN102695504A (zh) 2012-09-26
EA022119B1 (ru) 2015-11-30
EP2490688B1 (en) 2014-10-08
WO2011049946A1 (en) 2011-04-28
SI2490688T1 (sl) 2015-01-30
EP2490688A1 (en) 2012-08-29
KR20120093970A (ko) 2012-08-23
PT2490688E (pt) 2014-12-29
EA201270570A1 (ru) 2012-09-28
NZ622713A (en) 2015-07-31
PL2490688T3 (pl) 2015-03-31
HK1175112A1 (en) 2013-06-28
MX2012004577A (es) 2012-06-13
AU2010308306A1 (en) 2012-05-10
JP2016041715A (ja) 2016-03-31
CA2779233A1 (en) 2011-04-28
US20120245186A1 (en) 2012-09-27
BR112012009215A2 (pt) 2019-09-24
DK2490688T3 (en) 2014-12-08
HRP20141150T1 (hr) 2015-01-30
PH12012500748A1 (en) 2012-10-29
NZ599445A (en) 2014-04-30
RS53716B1 (sr) 2015-04-30
JP2013508378A (ja) 2013-03-07
CY1115902T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
ES2526566T3 (es) Terapia de combinación contra el cáncer con compuestos inhibidores de HSP90
US20140005145A1 (en) Combination breast cancer therapy with hsp90 inhibitory compounds
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
ES2594874T3 (es) Compuestos de triazol que modulan la actividad de HSP90
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
ES2340027T3 (es) Combinaciones para tratar el mieloma multiple.
US20160120849A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2560641A2 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2663305A1 (en) Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2012116247A1 (en) Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
WO2012162293A1 (en) Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2011149824A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012141796A2 (en) Prostate cancer therapy with hsp90 inhibitory compounds
EP2678013A1 (en) Combination therapy of hsp90 inhibitory compounds with radiotherapy
RU2020121162A (ru) Противоопухолевый агент
WO2011146803A1 (en) Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
ES2573295T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab
HK1175112B (en) Combination cancer therapy with hsp90 inhibitory compounds
ES2963706T3 (es) Masitinib para el tratamiento del cáncer de próstata resistente a la castración
WO2014034756A1 (ja) けいれん重積発作の治療用医薬組成物
WO2022216930A1 (en) Novel mda-9 antagonist with anti-metastatic potential